NKD2是一种用于研究骨肉瘤发展进程的新型标志物。
NKD2 a novel marker to study the progression of osteosarcoma development.
作者信息
Sun X-Z, Liao Y, Zhou C-M
机构信息
Department of Anatomy and Histoembryology, Peking University Health Science Center, Beijing, China.
出版信息
Eur Rev Med Pharmacol Sci. 2016 Jul;20(13):2799-804.
OBJECTIVE
Osteosarcoma is the most frequent metastatic bone tumor in the current era. An effective novel marker is essential at the current scenario for the identification of the tumor and to treat them in the early stage of osteosarcoma.
PATIENTS AND METHODS
In the present study, patients having metastatic and non-metastatic osteosarcoma samples were collected from the 23 patients along with the control. Microarray analysis was performed on both samples. The results were validated using Western blot analysis.
RESULTS
Microarray analysis confirms the up-regulation of NKD2 gene in the progression of osteosarcoma development. The results were validated using western blot analysis. Microarray in accordance with Western blot analysis helps to validate the expression of NKD2 in the progression of osteosarcoma development.
CONCLUSIONS
In short, NKD2 is the key molecular marker to study the progression of osteosarcoma development, and it may be used for better prognosis of the disease in early stage.
目的
骨肉瘤是当今最常见的转移性骨肿瘤。在当前情况下，一种有效的新型标志物对于骨肉瘤肿瘤的识别及其早期治疗至关重要。
患者与方法
在本研究中，从23例患者中收集了转移性和非转移性骨肉瘤样本以及对照样本。对这两种样本都进行了微阵列分析。结果通过蛋白质免疫印迹分析进行验证。
结果
微阵列分析证实了NKD2基因在骨肉瘤发展进程中上调。结果通过蛋白质免疫印迹分析得到验证。与蛋白质免疫印迹分析一致的微阵列有助于验证NKD2在骨肉瘤发展进程中的表达。
结论
简而言之，NKD2是研究骨肉瘤发展进程的关键分子标志物，并且它可用于该疾病早期更好的预后评估。
Zotero 插件